Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daizhuang Peng"'
Autor:
Daizhuang Peng, Sumei Xu, Ting Zou, Yahui Wang, Wenjuan Ouyang, Yalan Zhang, Chengmei Dong, Dai Li, Jie Guo, Qiuying Shen, Xiaolei Hu, Wenzhi Zhou, Xiaomin Li, Qun Qin
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background AD16 is a Class 1.1 new drug candidate for Alzheimer’s disease (AD), which has demonstrated potential benefits in AD by reducing neuroinflammation in preclinical studies. Herein, the pharmacokinetics (PK), safety, and tolerabili
Externí odkaz:
https://doaj.org/article/358e8135b8854330bee03778f3c368aa
Publikováno v:
European Journal of Medical Research, Vol 28, Iss 1, Pp 1-13 (2023)
Abstract Patients treated with hemodialysis are often immunocompromised due to concomitant disease. As a result, this population is at high risk of infection and mortality from COVID-19. In addition to symptomatic treatment, a series of antiviral dru
Externí odkaz:
https://doaj.org/article/00ebbe76c2a5478590aa5cc839c26aa6
Autor:
Chengmei Dong, Xiaonan Zhang, Yalan Zhang, Wenjuan Ouyang, Daizhuang Peng, Xiaomin Li, Dai Li, Qun Qin
Publikováno v:
Basicclinical pharmacologytoxicology.
Ticagrelor is the first reversible ADP P2Y12 receptor antagonist approved to treat acute coronary syndrome. To investigate the effects of food on the pharmacokinetics (PK), bioequivalence, and safety of ticagrelor tablets in healthy Chinese volunteer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c15a06d44aea6b2a0eda4a8d3bceb7
https://pubmed.ncbi.nlm.nih.gov/36617810
https://pubmed.ncbi.nlm.nih.gov/36617810